Experts’ corner : ADCs/ADCs Bispecific
The Experts Corner – Discover our discussion with Alain Beck of Pierre Fabre Laboratories on ADCs/Bispecific ADCs.
ADCs : antibodies and cytotoxic molecules united against tumours
From Paul Ehrlich’s early “magic bullet” concept to today’s approved therapeutics, Antibody-Drug Conjugates (ADCs) represent a major breakthrough in targeted cancer therapy. By combining the selectivity of monoclonal antibodies with the potency of cytotoxic agents, ADCs aim to eliminate tumor cells while sparing healthy tissues. This article dives into the evolution, design strategies, and key challenges of these complex biologics.
antibody-drug conjugates
This month’s MabDesign market analysis gives you an overview of the antibody-drug conjugates market and projects in development.